iShares MSCI EAFE ETF Experiences Big Inflow
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 14 2024
0mins
Should l Buy TEVA?
Source: NASDAQ.COM
- EFA's 52 Week Range: EFA's low point is $65.68 per share, and the high point is $82.16 per share.
- Comparison to Moving Average: Comparing the most recent share price to the 200-day moving average is a useful technical analysis technique.
- Exchange Traded Funds (ETFs): ETFs trade like stocks, with investors buying and selling "units" that can be created or destroyed based on demand.
- Monitoring Shares Outstanding: Weekly monitoring of shares outstanding data helps track ETFs experiencing notable inflows or outflows.
- Author's Disclaimer: The views and opinions expressed in the content are those of the author and may not reflect Nasdaq, Inc.'s views.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 32.280
Low
29.00
Averages
35.71
High
40.00
Current: 32.280
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Comparing Turnarounds: Pfizer vs. Teva
- Dividend Yield Comparison: Pfizer's dividend yield stands at 6.3%, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it more appealing to income-focused investors.
- Pfizer's Challenges and Responses: Facing key patent expirations and setbacks in new drug development, Pfizer has strategically acquired a promising GLP-1 drug candidate, demonstrating its resilience and ability to thrive amid industry fluctuations.
- Teva's Turnaround Risks: Teva is undergoing a significant business transformation to include both generics and new drugs, which increases its risk profile, especially as it currently does not offer dividends to attract income-seeking investors.
- Investor Choice: For turnaround investors, Pfizer may represent a superior option, particularly for those who value dividends, as Teva's business overhaul presents greater challenges compared to the typical industry headwinds Pfizer is navigating.
See More
Druckenmiller Cuts Pharma and Semiconductor Holdings
- Selling Top Performers: In his latest 13F filing, Druckenmiller reduced his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% cut, and also sold 222,000 shares of Taiwan Semiconductor Manufacturing (TSMC), a 29% reduction, indicating a cautious outlook on the future performance of these stocks.
- Teva's Financial Improvement: Under CEO Richard Francis, Teva has focused on high-margin novel drug development, leading to significant sales growth, with its stock price doubling since Druckenmiller's initial investment in Q3 2024, reflecting improved financial flexibility after years of cost-cutting and asset sales.
- TSMC's AI Advantage: TSMC, the world's leading chip fabricator, has also seen its stock price double since Druckenmiller opened a position, benefiting from its chip technology being a staple in AI-accelerated data centers, highlighting its critical role in the rapidly evolving tech landscape.
- New Investment Focus: Druckenmiller's 13F report revealed a purchase of 5,495,600 shares of the State Street Financial Select Sector SPDR ETF (XLF), making it his fund's second-largest holding, signaling optimism about the U.S. economic recovery, despite the Federal Reserve's easing cycle since September 2024, which could impact financial stocks' performance.
See More
Druckenmiller Reduces Stakes in Pharma and Semiconductor Stocks
- Pharmaceutical Stake Reduction: Druckenmiller cut his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% reduction, reflecting a profit-taking strategy after significant stock appreciation, indicating a cautious outlook on the pharmaceutical sector's future.
- Semiconductor Stake Cut: He also reduced his position in Taiwan Semiconductor by 222,000 shares, a 29% decrease, likely due to concerns over the stock's overheated performance amid the AI revolution, showcasing his sensitivity to market fluctuations.
- ETF Investment Increase: Druckenmiller purchased 5,495,600 shares of the State Street Financial Select Sector SPDR ETF, making it the fund's second-largest holding, signaling optimism about the U.S. economic recovery, particularly as rising interest rates could enhance financial sector profitability.
- Portfolio Dynamics: With an average holding period of 7.5 months for securities in his portfolio, Druckenmiller demonstrates a flexible investment strategy and rapid responsiveness to market changes, suggesting a keen awareness of future market trends.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
Blackstone and Teva Forge $400M Strategic Funding Agreement
- Strategic Funding Agreement: Blackstone Life Sciences has secured a $400 million strategic funding agreement with Teva Pharmaceutical to support the development of duvakitug, a phase 3 asset for ulcerative colitis and Crohn's disease, with funds allocated over four years.
- Milestone Payment Structure: Teva will pay Blackstone a milestone payment upon duvakitug's approval, and Blackstone is also eligible for commercial milestones and low single-digit royalties on global sales, enhancing its revenue potential significantly.
- Co-Development and Commercialization: Duvakitug will be co-developed and co-commercialized with Sanofi, a partnership that not only facilitates resource sharing but also accelerates the product's market entry, thereby improving competitive positioning.
- Clinical Data Support: Teva and Sanofi released phase 2b maintenance data on duvakitug in February, demonstrating the drug's potential in treating inflammatory bowel disease, which lays a solid foundation for subsequent clinical development.
See More
Blackstone Life Sciences Invests $400 Million to Support Teva's Duvakitug Development
- Strategic Investment Agreement: Blackstone Life Sciences will provide Teva with $400 million over four years to support the clinical development of duvakitug, which will accelerate Teva's innovative pipeline and drive long-term growth.
- Clinical Research Progress: Duvakitug is currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, demonstrating potential as a best-in-class therapy for these conditions, which could significantly impact patient care.
- Mutual Benefits of Collaboration: The partnership with Blackstone not only funds the development of duvakitug but also allows Blackstone to earn commercial milestones and low single-digit royalties on future sales, enhancing both companies' competitive positions in the market.
- Response to Market Demand: With approximately 4.9 million cases of IBD globally, the development of duvakitug aims to address this significant unmet medical need, aligning with Teva's Pivot to Growth strategy and strengthening its position in the biopharmaceutical sector.
See More
Comparing Turnarounds: Pfizer vs. Teva
- Dividend Yield Comparison: Pfizer's dividend yield stands at 6.3%, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it more appealing to income-focused investors.
- Pfizer's Challenges and Responses: Facing key patent expirations and setbacks in new drug development, Pfizer has strategically acquired a promising GLP-1 drug candidate, demonstrating its resilience and ability to thrive amid industry fluctuations.
- Teva's Turnaround Risks: Teva is undergoing a significant business transformation to include both generics and new drugs, which increases its risk profile, especially as it currently does not offer dividends to attract income-seeking investors.
- Investor Choice: For turnaround investors, Pfizer may represent a superior option, particularly for those who value dividends, as Teva's business overhaul presents greater challenges compared to the typical industry headwinds Pfizer is navigating.
See More
Druckenmiller Cuts Pharma and Semiconductor Holdings
- Selling Top Performers: In his latest 13F filing, Druckenmiller reduced his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% cut, and also sold 222,000 shares of Taiwan Semiconductor Manufacturing (TSMC), a 29% reduction, indicating a cautious outlook on the future performance of these stocks.
- Teva's Financial Improvement: Under CEO Richard Francis, Teva has focused on high-margin novel drug development, leading to significant sales growth, with its stock price doubling since Druckenmiller's initial investment in Q3 2024, reflecting improved financial flexibility after years of cost-cutting and asset sales.
- TSMC's AI Advantage: TSMC, the world's leading chip fabricator, has also seen its stock price double since Druckenmiller opened a position, benefiting from its chip technology being a staple in AI-accelerated data centers, highlighting its critical role in the rapidly evolving tech landscape.
- New Investment Focus: Druckenmiller's 13F report revealed a purchase of 5,495,600 shares of the State Street Financial Select Sector SPDR ETF (XLF), making it his fund's second-largest holding, signaling optimism about the U.S. economic recovery, despite the Federal Reserve's easing cycle since September 2024, which could impact financial stocks' performance.
See More
Druckenmiller Reduces Stakes in Pharma and Semiconductor Stocks
- Pharmaceutical Stake Reduction: Druckenmiller cut his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% reduction, reflecting a profit-taking strategy after significant stock appreciation, indicating a cautious outlook on the pharmaceutical sector's future.
- Semiconductor Stake Cut: He also reduced his position in Taiwan Semiconductor by 222,000 shares, a 29% decrease, likely due to concerns over the stock's overheated performance amid the AI revolution, showcasing his sensitivity to market fluctuations.
- ETF Investment Increase: Druckenmiller purchased 5,495,600 shares of the State Street Financial Select Sector SPDR ETF, making it the fund's second-largest holding, signaling optimism about the U.S. economic recovery, particularly as rising interest rates could enhance financial sector profitability.
- Portfolio Dynamics: With an average holding period of 7.5 months for securities in his portfolio, Druckenmiller demonstrates a flexible investment strategy and rapid responsiveness to market changes, suggesting a keen awareness of future market trends.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
Blackstone and Teva Forge $400M Strategic Funding Agreement
- Strategic Funding Agreement: Blackstone Life Sciences has secured a $400 million strategic funding agreement with Teva Pharmaceutical to support the development of duvakitug, a phase 3 asset for ulcerative colitis and Crohn's disease, with funds allocated over four years.
- Milestone Payment Structure: Teva will pay Blackstone a milestone payment upon duvakitug's approval, and Blackstone is also eligible for commercial milestones and low single-digit royalties on global sales, enhancing its revenue potential significantly.
- Co-Development and Commercialization: Duvakitug will be co-developed and co-commercialized with Sanofi, a partnership that not only facilitates resource sharing but also accelerates the product's market entry, thereby improving competitive positioning.
- Clinical Data Support: Teva and Sanofi released phase 2b maintenance data on duvakitug in February, demonstrating the drug's potential in treating inflammatory bowel disease, which lays a solid foundation for subsequent clinical development.
See More
Blackstone Life Sciences Invests $400 Million to Support Teva's Duvakitug Development
- Strategic Investment Agreement: Blackstone Life Sciences will provide Teva with $400 million over four years to support the clinical development of duvakitug, which will accelerate Teva's innovative pipeline and drive long-term growth.
- Clinical Research Progress: Duvakitug is currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, demonstrating potential as a best-in-class therapy for these conditions, which could significantly impact patient care.
- Mutual Benefits of Collaboration: The partnership with Blackstone not only funds the development of duvakitug but also allows Blackstone to earn commercial milestones and low single-digit royalties on future sales, enhancing both companies' competitive positions in the market.
- Response to Market Demand: With approximately 4.9 million cases of IBD globally, the development of duvakitug aims to address this significant unmet medical need, aligning with Teva's Pivot to Growth strategy and strengthening its position in the biopharmaceutical sector.
See More
